Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.

@article{PrezAndreu2009PharmacogeneticRO,
  title={Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.},
  author={Virginia P{\'e}rez-Andreu and Vanessa Rold{\'a}n and Ana Isabel Ant{\'o}n and Nuria Garc{\'i}a-Barber{\'a} and Javier Corral and Vicente Vicente and Roc{\'i}o Gonz{\'a}lez-Conejero},
  journal={Blood},
  year={2009},
  volume={113 20},
  pages={
          4977-9
        }
}
VKORC1 and CYP2C9 polymorphisms are used to predict the safe dose of oral anticoagulant therapy. A new variant of CYP4F2 (V433M) has recently been related to the required warfarin dose. We evaluated its influence in earliest response to acenocoumarol in 100 selected men who started anticoagulation (3 mg for 3 consecutive days). V433M genotype exerted a gene dosage-dependent effect on the decrease of factors II, VII, IX, and X in the earliest response to acenocoumarol, with homozygous 433V… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 37 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Similar Papers

Loading similar papers…